JP2018517419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517419A5 JP2018517419A5 JP2017565248A JP2017565248A JP2018517419A5 JP 2018517419 A5 JP2018517419 A5 JP 2018517419A5 JP 2017565248 A JP2017565248 A JP 2017565248A JP 2017565248 A JP2017565248 A JP 2017565248A JP 2018517419 A5 JP2018517419 A5 JP 2018517419A5
- Authority
- JP
- Japan
- Prior art keywords
- attenuated strain
- salmonella enterica
- seq
- salmonella
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803 | 2015-06-18 | ||
| EP15001803.4 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517419A JP2018517419A (ja) | 2018-07-05 |
| JP2018517419A5 true JP2018517419A5 (https=) | 2019-05-30 |
| JP6947649B2 JP6947649B2 (ja) | 2021-10-13 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565248A Active JP6947649B2 (ja) | 2015-06-18 | 2016-06-16 | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10905752B2 (https=) |
| EP (2) | EP3310379B1 (https=) |
| JP (1) | JP6947649B2 (https=) |
| KR (2) | KR20250024816A (https=) |
| CN (1) | CN107995868B (https=) |
| AU (1) | AU2016278588B2 (https=) |
| BR (1) | BR112017027378A2 (https=) |
| CA (1) | CA2989247C (https=) |
| DK (1) | DK3310379T3 (https=) |
| ES (2) | ES2760699T3 (https=) |
| HU (1) | HUE046631T2 (https=) |
| IL (1) | IL256076A (https=) |
| LT (1) | LT3310379T (https=) |
| MX (1) | MX2017016183A (https=) |
| PL (2) | PL3626262T3 (https=) |
| RU (1) | RU2018101722A (https=) |
| SI (1) | SI3310379T1 (https=) |
| WO (1) | WO2016202459A1 (https=) |
| ZA (1) | ZA201708439B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041375A1 (en) * | 2016-11-04 | 2018-05-11 | Vaximm Ag | Wt1 targeting dna vaccine for combination therapy |
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| US20230121528A1 (en) * | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| CA2853656C (en) | 2011-12-22 | 2020-12-29 | Vaximm Ag | Method of producing high yield attenuated salmonella strains |
| JP6325534B2 (ja) * | 2012-07-05 | 2018-05-16 | バクシム アクチェンゲゼルシャフト | 膵臓癌患者用ｄｎａワクチン |
| PL2897620T3 (pl) * | 2012-09-21 | 2020-11-02 | Intensity Therapeutics, Inc | Sposób leczenia nowotworu złośliwego |
| US9974845B2 (en) * | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| MX364922B (es) | 2013-04-25 | 2019-05-14 | Vaximm Ag | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. |
| SI3082850T1 (sl) * | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | DNA cepivo, ki cilja MSLN za imunoterapijo raka |
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
-
2016
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 PL PL19205420.3T patent/PL3626262T3/pl unknown
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 KR KR1020257001040A patent/KR20250024816A/ko active Pending
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
- 2016-06-16 EP EP19205420.3A patent/EP3626262B1/en active Active
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Ceased
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en not_active Ceased
- 2016-06-16 ES ES19205420T patent/ES2994561T3/es active Active
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517419A5 (https=) | ||
| Kallert et al. | Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy | |
| Fu et al. | Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects | |
| Shaw et al. | Immunology of adenoviral vectors in cancer therapy | |
| Pol et al. | Maraba virus as a potent oncolytic vaccine vector | |
| Kuryk et al. | Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model | |
| JP2011500718A5 (https=) | ||
| JP2020511139A5 (https=) | ||
| Farrera-Sal et al. | Evolving status of clinical immunotherapy with oncolytic adenovirus | |
| RU2016129044A (ru) | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Liu et al. | Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy | |
| US10987432B2 (en) | Therapeutic delivery and expression system, methods and uses thereof | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| RU2015103758A (ru) | Днк-вакцина для применения у пациентов с раком поджелудочной железы | |
| Chen et al. | Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma | |
| Nosaki et al. | A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity | |
| JP2021533789A5 (https=) | ||
| JP2007020586A5 (https=) | ||
| Zhao et al. | Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| Su et al. | Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors | |
| Kamensek et al. | Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer | |
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma |